Orgenesis to acquire 25% stake in Octomera from MM OS Holdings

Orgenesis entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners, for the acquisition of its approximate 25% stake in Octomera, the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera’s cell processing services, for the three calendar years 2025-2027, along with a portion of the proceeds attributable to Octomera’s cell processing services should there be a change of control in the next 10 years.